Artefenomel (OZ439): A Comprehensive Monograph on a Promising Antimalarial Candidate

Executive Summary

Artefenomel, also known by its development code OZ439, is a second-generation, fully synthetic 1,2,4-trioxolane antimalarial agent. It was developed as a leading candidate to succeed the current standard of care, artemisinin-based combination therapies (ACTs), with the ambitious goal of providing a single-dose oral cure for uncomplicated malaria. The molecule was rationally designed to retain the potent, rapid parasiticidal activity of the artemisinin endoperoxide pharmacophore while overcoming the primary pharmacokinetic limitation of existing artemisinins—a short half-life. Preclinical and early clinical studies confirmed this design, demonstrating potent activity against multiple Plasmodium species and a significantly prolonged plasma half-life, which formed the scientific basis for the single-dose treatment strategy.

Despite its initial promise, the extensive clinical development program for Artefenomel was ultimately terminated. This report provides a comprehensive analysis of the drug's journey, concluding that its failure was not due to a single catastrophic event but rather a confluence of interconnected factors. The core issue stemmed from fundamental physicochemical liabilities; the very molecular features that conferred its advantageous pharmacokinetic stability also resulted in poor aqueous solubility and high crystallinity. These properties created insurmountable challenges in developing a simple, reliable oral formulation. The resulting liquid suspension was difficult to administer, especially in the target pediatric population, and its absorption was highly dependent on co-administration with fatty food. This led to significant tolerability issues, most notably a high incidence of vomiting, which in turn caused variable and often sub-therapeutic drug exposure. Consequently, in pivotal Phase 2b clinical trials, Artefenomel, in combination with partner drugs such as piperaquine and ferroquine, consistently failed to achieve the stringent efficacy target of >95% cure rates required for a next-generation antimalarial. The story of Artefenomel thus serves as a critical case study in modern drug development, illustrating the delicate balance between pharmacodynamic potency, pharmacokinetic optimization, and the often-underestimated role of pharmaceutical sciences in translating a promising molecule into a viable medicine.

Introduction: The Imperative for Next-Generation Antimalarials

The Global Burden of Malaria and the Rise of Artemisinin Resistance

Malaria remains one of the most significant infectious diseases globally, posing a substantial public health threat, particularly in sub-Saharan Africa, Asia, and South America.[1] The cornerstone of modern malaria treatment is artemisinin-based combination therapy (ACT), a therapeutic strategy that has been instrumental in reducing malaria-associated morbidity and mortality over the past two decades.[3] ACTs, such as artemether-lumefantrine and artesunate-amodiaquine, combine a potent, fast-acting artemisinin derivative with a longer-acting partner drug to ensure complete parasite eradication and mitigate the development of resistance.[3]

However, the continued success of this strategy is under severe threat from the emergence and spread of parasite resistance to artemisinins. First identified in Southeast Asia, this resistance is characterized by delayed parasite clearance following treatment and is strongly associated with mutations in the Plasmodium falciparum Kelch13 (K13) gene.[8] The geographical expansion of artemisinin-resistant parasites, now increasingly reported in Africa, represents a global health emergency that could reverse decades of progress in malaria control and potentially lead to a resurgence of untreatable malaria.[11] This escalating crisis creates an urgent and undeniable imperative for the discovery and development of next-generation antimalarials with novel mechanisms of action and improved pharmacological profiles.

Limitations of Current Combination Therapies

Beyond the biological threat of resistance, current ACTs possess inherent operational limitations that contribute to their vulnerability. The standard treatment course for uncomplicated malaria requires a three-day, twice-daily dosing regimen.[4] In resource-limited settings, ensuring patient adherence to this full course of therapy is a major challenge. Incomplete treatment not only risks therapeutic failure for the individual patient but also exposes the residual parasite population to sub-lethal drug concentrations, creating an ideal environment for the selection and propagation of drug-resistant strains.[4] This dynamic places immense pressure on both the artemisinin component and the partner drug, accelerating the timeline to clinical resistance for the entire combination.

Therefore, a primary strategic goal for the next generation of antimalarials has been to move beyond the constraints of multi-day regimens. The ideal candidate would enable a simplified, and preferably single-dose, treatment course. Such a regimen, termed a "Single Encounter Radical Cure" (SERC), could be administered under direct observation, thereby eliminating patient adherence as a variable, ensuring complete parasite eradication, and serving as a powerful tool to combat the spread of resistance.[14]

Artefenomel: A Synthetic Ozonide Designed for a Single-Dose Cure

Artefenomel (OZ439) was developed as a direct response to these challenges and emerged as a leading candidate for a next-generation, single-dose antimalarial therapy.[1] It is a fully synthetic peroxide, specifically an ozonide of the 1,2,4-trioxolane class, which was engineered to retain the essential endoperoxide bridge pharmacophore responsible for the potent, rapid parasiticidal activity of the natural product artemisinin.[19] The key innovation in Artefenomel's design was the incorporation of structural modifications aimed at dramatically improving its pharmacokinetic profile. Unlike the artemisinin derivatives, which are rapidly cleared from the body, Artefenomel was designed for a significantly longer elimination half-life.[9] This extended exposure profile was the fundamental basis for its potential to achieve a single-dose cure, a paradigm shift from the multi-day ACT regimens.[14]

The development of Artefenomel was a major strategic undertaking, spearheaded by the non-profit product development partnership Medicines for Malaria Venture (MMV) in collaboration with major pharmaceutical partners, including Sanofi and GlaxoSmithKline (GSK).[1] This program represented a sophisticated strategic response to the multifaceted challenges of malaria control. It was not merely an effort to create a more potent drug, but to fundamentally alter the treatment paradigm. The concept of a single-dose, directly observed therapy was a direct countermeasure to the behavioral and logistical vulnerabilities of existing treatments, aiming to create a more "resistance-proof" therapy by ensuring complete and reliable parasite eradication.

Molecular Profile and Physicochemical Properties

Identification, Structure, and Chemical Class

Artefenomel is the International Nonproprietary Name (INN) for a small molecule drug candidate identified by the development code OZ439.[21] It is registered in major chemical and pharmacological databases under identifiers such as DrugBank ID DB11809 and CAS Number 1029939-86-3.[21] For research and development, it has been formulated as a free base and as various salt forms, including Artefenomel mesylate (CAS 1029939-87-4) and tosylate (CAS 1310917-29-3), to modulate its physicochemical properties.[17]

The molecular formula of Artefenomel is $C_{28}H_{39}NO_{5}$, corresponding to an average molecular weight of 469.62 g/mol.[17] Structurally, it is a synthetic organic compound classified as an ozonide, specifically a 1,2,4-trioxolane.[10] This classification is defined by the presence of a five-membered ring containing three oxygen atoms, two of which form an endoperoxide bridge ($C-O-O-C$). This endoperoxide moiety is the critical pharmacophore it shares with the artemisinin class of antimalarials and is essential for its parasiticidal activity.[19] A key structural feature that distinguishes Artefenomel from first-generation synthetic ozonides is the incorporation of a sterically bulky adamantane ring system. This modification was a deliberate design choice intended to shield the molecule from metabolic degradation, thereby increasing its stability in blood plasma and prolonging its pharmacokinetic half-life.[19] The molecule also contains a morpholine moiety and is classified within the broader chemical class of phenol ethers.[21]

Physicochemical Characteristics and Formulation Challenges

The physicochemical properties of Artefenomel were central to both its therapeutic potential and its ultimate failure. The molecule is described as amphiphilic but is characterized by very poor aqueous solubility.[28] This is consistent with its highly lipophilic nature, as quantified by a predicted partition coefficient (XLogP) of 5.34, which indicates a strong preference for lipid environments over aqueous ones.[19] This poor solubility proved to be a major obstacle throughout its development.[26]

A critical factor contributing to this solubility issue is the molecule's high degree of structural symmetry. The rigid and symmetric adamantane and cyclohexyl rings create a molecule that packs very efficiently into a stable crystal lattice.[11] Molecules with high crystal packing energy tend to form crystals that are thermodynamically stable and, consequently, slow to dissolve in aqueous media.[26] This inherent property of Artefenomel was the root cause of the significant formulation challenges that plagued its development program.

These physicochemical liabilities made it exceedingly difficult to formulate Artefenomel into a conventional, simple-to-administer solid oral dosage form, such as a tablet or capsule, that could reliably deliver the high doses required for efficacy.[11] Instead, the drug had to be developed as granules for oral suspension, which were mixed with liquid prior to administration.[29] Clinical protocols often specified co-administration with fatty substances like full-cream milk to create a lipid-based formulation in situ to enhance absorption.[28] This "finicky nature" of its administration complicated the execution of clinical trials, introduced variability in drug exposure, and was particularly problematic for pediatric populations, who are the primary target for antimalarial therapies.[11]

The molecular design of Artefenomel thus represents a classic "Faustian bargain" in medicinal chemistry. The strategic incorporation of the bulky, lipophilic adamantane ring was highly successful in achieving the primary pharmacokinetic goal: it increased metabolic stability and dramatically prolonged the drug's half-life compared to artemisinins.[19] However, this same structural feature was a primary contributor to the molecule's high symmetry and lipophilicity, which in turn led to its poor solubility and high crystallinity. In essence, the modification that solved the pharmacokinetic problem simultaneously created a fatal flaw in the pharmaceutical profile. The drug was a victim of its own success, where optimizing for a critical "drug-like" property (a long half-life) came at the direct and ultimately insurmountable expense of another (solubility and formulatability). This outcome highlights a critical lesson in drug development: the necessity of integrated, multi-parameter optimization, where ADME (Absorption, Distribution, Metabolism, and Excretion) properties and pharmaceutical "developability" are considered in parallel from the earliest stages of drug discovery.

Table 1: Key Identifiers and Physicochemical Properties of Artefenomel

Property	Value	Reference(s)
Generic Name	Artefenomel	22
Development Code	OZ439	21
DrugBank ID	DB11809	21
CAS Number	1029939-86-3	22
Molecular Formula	$C_{28}H_{39}NO_{5}$	21
Molecular Weight	469.6 g/mol	22
Chemical Class	Synthetic Ozonide / 1,2,4-trioxolane	24
Key Structural Features	Endoperoxide bridge, Adamantane ring, Morpholine moiety	19
XLogP	5.34	19
Hydrogen Bond Acceptors	5	19
Hydrogen Bond Donors	0	19
Solubility Profile	Poorly water-soluble, Lipophilic	26

Preclinical and Clinical Pharmacology

Mechanism of Antimalarial Action

The antimalarial mechanism of Artefenomel is fundamentally similar to that of the artemisinin class of drugs, centered on the bioactivation of its endoperoxide bridge.[2] This activation process is initiated within the malaria parasite, specifically inside its digestive vacuole, a compartment where the parasite digests host hemoglobin. The breakdown of hemoglobin releases large quantities of heme, which contains iron in its ferrous ($Fe^{2+}$) state. Artefenomel's endoperoxide bridge undergoes a reductive cleavage reaction upon interaction with this ferrous heme.[2]

This reaction is highly energetic and results in the formation of highly reactive and cytotoxic carbon-centered free radicals.[3] Once formed, these radicals are non-specific and promiscuously attack a wide range of essential biomolecules within the parasite. The primary mechanism of cell death is believed to be the widespread, covalent alkylation of parasite proteins, which disrupts their function and leads to a catastrophic failure of cellular homeostasis.[3] Some evidence also suggests that Artefenomel may disrupt the parasite's mitochondrial function, leading to the generation of toxic reactive oxygen species (ROS) that further contribute to oxidative stress and cell death.[1]

While the core mechanism is shared with artemisinins, subtle but important differences have been identified. In vitro studies comparing the two have shown that, in the presence of the biologically abundant antioxidant glutathione, artemisinin efficiently alkylates heme itself, forming stable heme-drug adducts. In contrast, Artefenomel does not readily form these adducts under the same conditions. Instead, the carbon-centered radical generated from Artefenomel activation reacts preferentially with the thiol group of glutathione.[8] This finding suggests that the downstream targets of the two drug classes may differ in proportion, with Artefenomel having a greater propensity for alkylating proteins and other non-heme biological targets compared to artemisinin. This distinction could have implications for their respective activity profiles, potential for cross-resistance, and the specific mechanisms by which K13 mutations affect their efficacy. Additionally, some preliminary research has suggested potential off-target activity, including antiviral effects against SARS-CoV-2, possibly through the downregulation of the ACE2 receptor, though this is outside its primary therapeutic indication.[32]

Pharmacodynamics: In Vitro Potency and In Vivo Parasite Clearance

Artefenomel exhibits potent antimalarial activity across a range of preclinical and clinical models. In vitro assays have consistently demonstrated its high potency against various laboratory-adapted and clinical strains of P. falciparum. Reported 50% inhibitory concentrations ($IC_{50}$) and 50% lethal concentrations ($LC_{50}$) are typically in the low nanomolar range, for example, an $IC_{50}$ of 1.6 nM against the drug-sensitive PfNF54 strain and $LC_{50}$ values between 4.4 and 8.7 nM against other strains.[24] This activity is broad, affecting all asexual erythrocytic stages of the parasite, including the early ring stages that are a key target for rapid symptom resolution.[18] This potent in vitro profile translated effectively to in vivo animal models, where a single 30 mg/kg oral dose of Artefenomel was shown to be 100% curative in a mouse model of Plasmodium berghei infection.[24]

In human studies, Artefenomel demonstrated the rapid parasite clearance characteristic of the endoperoxide class in patients with both P. falciparum and P. vivax malaria.[3] The key pharmacodynamic parameters used to quantify this effect are the parasite clearance half-life and the parasite reduction ratio (PRR).

• Parasite Clearance Half-Life: This metric describes the time required to reduce the parasite density in the blood by 50%. Studies reported values ranging from 3.6 hours to 8.67 hours, depending on the specific trial, the dose administered, and the parasite species being treated.[3]
• Parasite Reduction Ratio (PRR): This measures the fold-reduction in parasitemia over a specific time interval, typically 48 hours ($PRR_{48}$). A single 500 mg dose of Artefenomel was shown to achieve a $PRR_{48}$ of greater than 10,000, indicating a profound and rapid reduction in parasite burden.[36]

Pharmacokinetic/pharmacodynamic (PK/PD) modeling, which integrates drug exposure data with parasite response, was used to estimate the minimum inhibitory concentration (MIC) required to suppress parasite growth. These models predicted an MIC of approximately 4.1 ng/mL for P. falciparum and a lower MIC of 0.62 ng/mL for P. vivax, reflecting its potent activity against both major human malaria parasites.[31]

Pharmacokinetics: An ADME Profile Defined by a Long Half-Life

The pharmacokinetic profile of Artefenomel was its most defining feature and the primary rationale for its development as a single-dose therapy.

• Absorption: Artefenomel is orally active, with peak plasma concentrations ($t_{max}$) typically reached approximately 3 to 4 hours after administration.[18] Its absorption is significantly influenced by food. Co-administration with a high-fat meal, such as full-cream milk, was shown to increase its oral bioavailability and overall drug exposure (AUC) by a factor of 3 to 4.5 compared to administration in a fasted state.[28] This pronounced positive food effect is attributed to the enhanced solubilization of the highly lipophilic drug by lipids and bile salts in the gastrointestinal tract, a common phenomenon for drugs of this class.[28]
• Distribution: While specific data on the volume of distribution are limited, the drug's high lipophilicity suggests it distributes extensively into tissues throughout the body.
• Metabolism: Artefenomel undergoes hepatic metabolism. The primary metabolic pathway involves the oxidation of the adamantane ring, leading to the formation of hydroxylated metabolites that are largely devoid of antimalarial activity.[37] Importantly, Artefenomel does not appear to be a significant inducer of major drug-metabolizing enzymes like CYP3A4, reducing the potential for certain types of drug-drug interactions.[37] Compared to some of its structural analogs, it has demonstrated improved stability in human liver microsomes in vitro, consistent with its design goal of reduced metabolic clearance.[26]
• Elimination: The elimination of Artefenomel is characterized by a multiphasic decline in plasma concentrations, culminating in a remarkably long terminal elimination half-life. This was the key advantage of Artefenomel over existing artemisinins. While the half-life of artemisinin derivatives is typically less than 10 hours, estimates for Artefenomel's half-life range from 25-30 hours in early studies to approximately 50 hours in later patient trials, with some studies reporting values as high as 95 hours.[2] This extended half-life ensures that parasiticidal concentrations of the drug are maintained in the body for several days following a single dose. The primary route of elimination is through metabolism, as urinary clearance of the parent drug and its metabolites is negligible.[37]

The pharmacokinetic profile of Artefenomel, while successful in achieving the goal of a long half-life, simultaneously introduced a critical vulnerability into its clinical application. The very long half-life was the foundation of the single-dose cure strategy, designed to provide sustained drug pressure to eradicate all parasites. However, the pronounced and variable food effect created a double-edged sword. Achieving the necessary therapeutic exposure was highly dependent on co-administration with a fatty meal. This created a significant risk of treatment failure in the real-world clinical setting, particularly for the primary target population: young, febrile, and often nauseous children with malaria, who may be unable to tolerate or retain a meal. For a multi-day therapy, a single poorly absorbed dose can be compensated by subsequent doses. For a single-dose therapy, there is no second chance. A patient who cannot eat or who vomits the drug and meal receives a sub-therapeutic dose, leading to treatment failure. Thus, the drug's pharmacokinetic dependency on food created a fragile therapeutic paradigm that was poorly matched to the clinical realities of its intended use, a factor that would prove critical in its eventual downfall.

Table 2: Summary of Key Pharmacokinetic Parameters of Artefenomel from Clinical Studies

Parameter	Value Range	Study Population / Conditions	Reference(s)
$T_{max}$ (Time to Peak Conc.)	3 - 4 hours	Healthy Volunteers & Malaria Patients	18
Elimination Half-life ($t_{1/2}$)	25 - 95 hours	Healthy Volunteers & Malaria Patients	2
Oral Bioavailability / Food Effect	3- to 4.5-fold increase in exposure with food (milk)	Healthy Volunteers	28
Route of Elimination	Primarily hepatic metabolism; negligible urinary clearance	Healthy Volunteers	37
Key Metabolites	Inactive hydroxylated adamantane metabolites	Healthy Volunteers	37

Clinical Development Program and Efficacy Analysis

Overview of the Clinical Trial Landscape

The clinical development of Artefenomel was a comprehensive program designed to rigorously evaluate its potential as a single-dose antimalarial therapy. The program progressed logically from initial safety and pharmacokinetic assessments in healthy volunteers (Phase 1) to proof-of-concept and dose-ranging studies in patients with malaria (Phase 2). Key studies included a first-in-human trial (NCT00928083) to establish safety in healthy subjects [41], followed by Phase 2a trials in patients with uncomplicated P. falciparum or P. vivax malaria to characterize its monotherapy activity (e.g., NCT01213966).[42] Recognizing the need for combination therapy to prevent resistance and ensure cure, the program then advanced to evaluate Artefenomel in combination with various long-acting partner drugs. The most prominent of these were the large-scale Phase 2b trial with piperaquine (PQP) (NCT02083380) and a Phase 2a study with ferroquine (FQ) (NCT03660839).[29] An exploratory Phase 1b study also investigated a combination with another novel agent, DSM265 (NCT02389348), in an induced blood-stage malaria (IBSM) model.[40] The consistent, overarching goal of this extensive program was to identify a combination that could achieve a "Single Encounter Radical Cure".[14]

Efficacy as Monotherapy: Rapid Action, Persistent Recrudescence

Early-phase clinical studies, both in malaria patients and in healthy volunteers using the IBSM model, rapidly established the core pharmacodynamic profile of Artefenomel monotherapy: potent, fast-acting, but ultimately non-curative.[18] Single oral doses ranging from 200 mg to 500 mg consistently produced a dramatic and rapid initial reduction in parasite burden, confirming the drug's potent intrinsic activity.[36]

However, a critical and recurring finding in these monotherapy trials was a high rate of parasite recrudescence. After the initial clearance phase, parasites would reappear in the blood of a significant proportion of subjects, typically 11 to 14 days after dosing.[31] This phenomenon was observed even at the higher doses tested (e.g., 500 mg), indicating that while Artefenomel could clear the vast majority of parasites, it was unable to completely eradicate the infection when used alone.[36] This outcome was not unexpected for a fast-acting compound with a mechanism similar to artemisinins and served as definitive proof that Artefenomel, like all artemisinin-class drugs, would require a long-acting partner drug to achieve curative efficacy and prevent the emergence of resistance.

Efficacy in Combination Therapy: Failure to Achieve Target Cure Rates

The true test of Artefenomel's potential lay in its performance as part of a combination therapy. Unfortunately, despite being tested with multiple partners, the program failed to identify a regimen that could consistently meet the high efficacy bar required for a next-generation antimalarial.

The Artefenomel-Piperaquine (PQP) Program

The largest and most pivotal study was the Phase 2b trial (NCT02083380) that combined a fixed 800 mg dose of Artefenomel with three ascending doses of the established antimalarial piperaquine (640 mg, 960 mg, and 1440 mg).[45] The primary objective was to achieve a cure rate, defined as the PCR-adjusted Adequate Clinical and Parasitological Response at Day 28 (ACPR28), of greater than 95%. The trial unequivocally failed to meet this endpoint.[3] The observed ACPR28 rates were disappointingly low, ranging from 68.4% to 78.6% across the three dose groups, well below the target threshold.[3] The efficacy was particularly poor in two critical subpopulations: children aged 2 years or younger, where the cure rate was only 52.7%, and in patients from Vietnam, a region with a high prevalence of artemisinin-resistant parasites.[15]

The Artefenomel-Ferroquine (FQ) Program

Following the failure with piperaquine, a Phase 2a study (NCT03660839) was conducted to evaluate Artefenomel in combination with another partner drug, ferroquine.[29] This trial tested three doses of Artefenomel (300 mg, 600 mg, and 1000 mg) combined with a fixed 400 mg dose of ferroquine. The results were similarly discouraging. The primary analysis failed to demonstrate a statistically significant contribution of Artefenomel exposure to the overall efficacy of the combination.[50] While adding Artefenomel did accelerate the initial rate of parasite clearance compared to ferroquine alone (median time to clearance of 30.0 hours vs. 56.1 hours), the ultimate cure rates were not sufficiently high or dose-dependent. The ACPR28 rates plateaued at around 90%, failing to consistently surpass the target efficacy threshold.[50]

Exploratory Combination with DSM265

An early-phase study (NCT02389348) in healthy volunteers with induced malaria infection provided some promising initial data for a combination of Artefenomel with DSM265, a novel agent with a different mechanism of action.[40] The combination was well-tolerated and demonstrated effective initial parasite clearance.[40] However, this partnership did not progress to late-stage patient trials before the broader Artefenomel development program was discontinued.

The clinical development program of Artefenomel reveals a narrative of consistent underperformance. There was no single, isolated failure, but rather a cumulative body of evidence showing that the drug, despite its theoretical promise, was not robust enough to succeed in the clinical arena. The failure to achieve high cure rates in young African children—the most important target population for any new antimalarial—was a particularly critical blow. This specific failure suggests that the drug's complex pharmacology was unable to overcome the combined challenges of high parasite burdens, lower host immunity, and the practical difficulties of administration (e.g., food dependency, vomiting) inherent in this vulnerable patient group. The program was not terminated because of one negative trial, but because the weight of evidence from multiple trials, with multiple partners, and in multiple populations demonstrated that it could not reliably achieve the level of excellence required to replace the current standard of care.

Table 3: Overview of Major Clinical Trials for Artefenomel

ClinicalTrials.gov ID	Phase	Study Population	Intervention(s) (Doses)	Primary Endpoint	Key Efficacy Outcome	Reference(s)
NCT00928083	1	Healthy Volunteers	Artefenomel Monotherapy	Safety & Tolerability	Established initial safety profile	41
NCT01213966	2a	P. falciparum / P. vivax Patients	Artefenomel Monotherapy (200, 400, 800, 1200 mg)	Parasite Reduction Rate	Rapid parasite clearance but high recrudescence rate	18
NCT02083380	2b	P. falciparum Patients (Africa & Asia)	Artefenomel (800 mg) + Piperaquine (640, 960, 1440 mg)	Day 28 PCR-adjusted ACPR	Failed to meet >95% target; ACPR28 ranged 68.4% - 78.6%	15
NCT03660839	2a	P. falciparum Patients (Africa)	Artefenomel (300, 600, 1000 mg) + Ferroquine (400 mg)	Contribution of Artefenomel to ACPR	No significant contribution demonstrated; ACPR28 ~90%	29
NCT02389348	1b	Healthy Volunteers (IBSM model)	Artefenomel (200 mg) + DSM265 (50, 100 mg)	Safety & Antimalarial Activity	Combination was well-tolerated and showed rapid parasite clearance	40

Safety, Tolerability, and Drug Interaction Profile

Consolidated Safety and Tolerability Findings

Across its clinical development program, Artefenomel was generally found to have an acceptable safety profile. In Phase 1 studies involving healthy volunteers, single doses up to 1600 mg were well-tolerated.[18] In studies conducted in patients with acute malaria, the majority of reported adverse events (AEs) were of mild to moderate severity and were largely indistinguishable from the typical signs and symptoms of the underlying disease, such as headache, fatigue, and myalgia.[18] Importantly, no treatment-related deaths were reported, and the incidence of serious adverse events (SAEs) considered related to the study drug was very low across the major trials.[40]

Analysis of Key Adverse Events and Cardiovascular Risk

While the overall safety profile was manageable, several specific AEs were noteworthy and had significant clinical implications.

• Gastrointestinal Events: The most clinically significant tolerability issue was vomiting. In the pivotal Phase 2b trial of Artefenomel plus piperaquine, which predominantly enrolled young children, vomiting was reported in 28.8% of participants.[15] This was not merely a comfort or safety issue; it was a critical factor that directly impacted efficacy. Subsequent analyses revealed a clear association between the occurrence of vomiting and lower plasma drug exposures, which in turn correlated with a higher risk of treatment failure.[53] This finding transforms a common "tolerability" problem into a primary "efficacy" problem, especially within the unforgiving paradigm of a single-dose therapy where achieving adequate drug absorption from that one dose is paramount.
• Hepatobiliary Events: Asymptomatic, mild-to-moderate, and transient elevations in liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were observed in some study participants.[18] These changes were generally not found to be dose-dependent and were often considered to be a consequence of the malaria infection itself, which can cause hepatic inflammation, rather than a direct drug-induced liver injury.
• Cardiovascular Safety (QTc Prolongation): The potential for a drug to prolong the QT interval of the electrocardiogram is a key safety concern for all new antimalarials, as it can increase the risk of life-threatening cardiac arrhythmias. While there were isolated reports of QTcF intervals exceeding 450 ms in patients receiving very high doses (1200 mg) of Artefenomel monotherapy, the dedicated combination therapy trials provided more reassuring data.[18] The Artefenomel-ferroquine study, for example, reported no cases of clinically significant QTcF prolongation (i.e., ≥500 ms or an increase of >60 ms from baseline), suggesting that within the therapeutically relevant dose range, the cardiovascular risk was manageable.[50]

Clinically Significant Drug-Drug Interactions

The potential for drug-drug interactions is a critical consideration for any new therapeutic agent.

• Pharmacokinetic Interactions: Clinical studies investigating Artefenomel in combination with partner drugs like DSM265 and piperaquine found no evidence of significant pharmacokinetic interactions; the drugs did not appear to alter each other's absorption, metabolism, or elimination.[3]
• Pharmacodynamic Interactions: Based on its known pharmacology and that of other endoperoxides, Artefenomel has a high potential for additive pharmacodynamic interactions when co-administered with other drugs that share similar effects.
• Increased Risk of QTc Prolongation: Co-administration with other drugs known to prolong the QT interval would be expected to increase this risk. This includes other antimalarials such as artemether, lumefantrine, and mefloquine, as well as drugs from other classes, notably phenothiazine antipsychotics (e.g., chlorpromazine, thioridazine).[21]
• Increased Risk of Methemoglobinemia: A potential risk identified for Artefenomel is an increased risk of methemoglobinemia, a condition where hemoglobin is unable to effectively release oxygen to the body's tissues. This risk is predicted to be elevated when Artefenomel is combined with a range of other agents, most notably local anesthetics (e.g., benzocaine, lidocaine, prilocaine) and other specific drugs like dapsone and ambroxol.[21]

The tolerability profile of Artefenomel provides a crucial insight into its clinical failure. The high incidence of vomiting was not a peripheral safety concern but was instead a central, efficacy-limiting factor. The entire strategy of a single-dose cure rests on the reliable delivery of a single, fully absorbed, curative dose. Any event that prevents this, such as vomiting, is a direct mechanism of treatment failure. The likely contribution of the drug's difficult formulation to its poor gastrointestinal tolerability created a vicious cycle: poor physicochemical properties necessitated a challenging formulation, which led to poor tolerability and vomiting, which in turn resulted in low and variable drug exposure, ultimately causing the treatment to fail.

Table 4: Summary of Potential Drug-Drug Interactions with Artefenomel

Interacting Drug Class	Specific Examples	Potential Clinical Effect	Mechanism	Reference(s)
Other Antimalarials	Artemether, Lumefantrine, Mefloquine	Increased risk of QTc prolongation	Additive Pharmacodynamic Effect	21
Antipsychotics (Phenothiazines)	Chlorpromazine, Thioridazine, Perphenazine	Increased risk of QTc prolongation	Additive Pharmacodynamic Effect	21
Local Anesthetics	Lidocaine, Benzocaine, Prilocaine, Bupivacaine	Increased risk of Methemoglobinemia	Pharmacodynamic Interaction	21
Other Specific Agents	Dapsone, Ambroxol, Meloxicam	Increased risk of Methemoglobinemia or other adverse effects	Pharmacodynamic Interaction	21

Synthesis, Formulation, and the Obstacle of Drug Delivery

Synthetic Pathway Overview

A key advantage of Artefenomel over the semi-synthetic artemisinin derivatives is that it is a fully synthetic molecule.[13] This circumvents the reliance on the agricultural sourcing of Artemisia annua (sweet wormwood), which can lead to variability in supply and cost for artemisinin production.[13] The discovery of Artefenomel was the culmination of an extensive medicinal chemistry campaign involving rigorous structure-activity relationship (SAR) studies. This effort aimed to optimize the molecular structure starting from the first-generation synthetic ozonide, arterolane (OZ277), to achieve a superior pharmacokinetic profile.[13] While detailed, proprietary synthesis routes are not fully public, published literature provides an outline of the general synthetic strategy used to prepare Artefenomel and its analogs, and includes detailed procedures for the synthesis of key chemical precursors, such as 3-(4-Acetoxyphenyl)cyclohexan-1-one.[13]

The Physicochemical Hurdles to a Viable Oral Formulation

The downfall of the Artefenomel program can be traced directly to the insurmountable difficulties in creating a viable oral drug product. This was not a failure of pharmacology but a failure of pharmaceutical science.

• The Core Problem: As detailed previously, the molecule's inherent physicochemical properties were profoundly unfavorable for oral drug delivery. The combination of high lipophilicity (poor aqueous solubility) and high molecular symmetry resulted in the formation of a highly stable, crystalline solid that dissolved very slowly in the aqueous environment of the gastrointestinal tract.[11]
• Consequences for Delivery: These properties made it effectively impossible to formulate a simple, robust, and reliable conventional oral dosage form like a tablet. The high dose required for efficacy in humans (800 mg) was particularly challenging to deliver from such a poorly soluble compound.[26] Consequently, the development team was forced to pursue more complex formulations, such as granules for oral suspension, which must be reconstituted with liquid before administration. This is a less convenient and potentially less accurate method of dosing compared to a fixed-dose tablet.[11]
• Clinical Impact: The reliance on a liquid suspension, often requiring co-administration with milk to improve absorption, had direct and negative consequences in the clinical setting. This complex administration requirement likely contributed to the poor gastrointestinal tolerability, leading to the high rates of vomiting observed in pediatric trials. The combination of vomiting and the highly variable, food-dependent absorption meant that achieving consistent, therapeutic drug exposure across a diverse patient population was extremely difficult. This variability undermined the very foundation of the single-dose cure strategy, which requires absolute reliability in drug delivery.[11]
• Cessation of Development: Ultimately, these formulation and drug delivery challenges were deemed insurmountable. The inability to create a simple, effective, and well-tolerated oral product that could reliably deliver the required dose led to the termination of the entire clinical development program in early 2025.[11]

Post-Hoc Research and Future Directions

The failure of Artefenomel prompted retrospective analysis and new research aimed at overcoming the specific chemical flaw that led to its demise. A research group at the University of California, San Francisco (UCSF) hypothesized that the core problem was the molecule's high symmetry. They designed and synthesized a desymmetrized regioisomer of Artefenomel, named RLA-3107.[26] By strategically rearranging the atoms in the molecule's periphery, they were able to disrupt the efficient crystal packing without altering the core endoperoxide pharmacophore. The resulting molecule was found to dissolve much more readily while retaining the potent in vitro and in vivo antimalarial activity of the original Artefenomel.[11] This work demonstrates that the underlying chemical class remains highly promising and offers a rational path forward for designing next-generation ozonides with improved "developability."

The story of Artefenomel serves as a powerful and cautionary tale in modern drug development. It is a clear indictment of a linear, siloed approach where different scientific disciplines operate in sequence rather than in parallel. The medicinal chemists were successful in designing a molecule with potent pharmacology and an ideal pharmacokinetic profile. The project advanced all the way to late-stage clinical trials, representing a massive investment of time, resources, and patient participation. However, it ultimately failed because of a fundamental pharmaceutical science problem—formulatability—that was inherent to the molecule from its inception. The fact that this "showstopper" issue was only fully appreciated after extensive clinical investigation suggests that key "developability" metrics, such as solubility, crystallinity, and formulatability, were not given sufficient weight during the initial lead optimization and candidate selection phases. The post-hoc success of the UCSF group in chemically solving the problem underscores that the core concept was sound, but the specific candidate chosen was flawed. This experience validates the modern drug development paradigm of "design for developability," which insists that pharmaceutical properties must be assessed and optimized in parallel with efficacy and safety from the very beginning of a program to avoid such costly late-stage failures.

Concluding Analysis: The Rise and Fall of a Promising Candidate

A Synthesis of Artefenomel's Potential and Pitfalls

The trajectory of Artefenomel from a leading next-generation antimalarial to a discontinued candidate is a story of immense potential thwarted by fundamental pitfalls. The drug was a product of rational design, successfully engineered to address the primary pharmacokinetic weakness of the artemisinin class. It demonstrated potent, rapid parasiticidal activity and, crucially, a long elimination half-life that provided the scientific foundation for the highly sought-after goal of a single-dose cure for malaria. This potential was not merely theoretical; it was confirmed in preclinical models and early human trials.

However, this promise was ultimately unrealized due to a cascade of interconnected failures that originated from the molecule's own chemical nature. Its poor physicochemical properties—specifically, low aqueous solubility and high crystallinity—created an insurmountable barrier to effective drug delivery. This led to complex and unreliable formulations, which in turn caused significant tolerability issues, particularly vomiting in children. This poor tolerability, combined with a strong food-dependent absorption, resulted in highly variable and often sub-therapeutic drug exposures in the very patient population it was designed to treat. The inevitable consequence was a failure to meet the stringent efficacy targets in pivotal clinical trials, leading to the termination of the program. Artefenomel was not defeated by a lack of potency or by unexpected toxicity, but by the practical, real-world challenge of getting the molecule from the bottle into the patient's bloodstream reliably.

Lessons for Future Antimalarial Drug Development

The comprehensive story of Artefenomel provides several critical lessons that must inform future drug discovery and development efforts, particularly in the field of infectious diseases.

• The Primacy of Formulation and Developability: The Artefenomel program is a stark and costly reminder that a potent active pharmaceutical ingredient is useless if it cannot be effectively delivered to its site of action. The concept of "developability"—assessing a molecule's suitability for formulation and manufacturing—cannot be an afterthought. It must be a core criterion, evaluated in parallel with potency and safety, from the earliest stages of lead optimization and candidate selection. Future programs must integrate the expertise of pharmaceutical scientists from their inception to avoid advancing molecules with inherent, fatal flaws in their physical properties.
• The Exceptionally High Bar for a Single-Dose Cure: The goal of a Single Encounter Radical Cure (SERC) is strategically brilliant but operationally unforgiving. Achieving a cure rate of over 95% with a single administration leaves absolutely no margin for error in drug delivery or exposure. This demands a drug with not only a wide therapeutic index but also a robust, simple, and reliable formulation that performs consistently across diverse patient populations, including those who are sick, malnourished, or unable to adhere to complex instructions like taking a drug with a specific type of meal. Artefenomel possessed none of these formulation characteristics.
• The Importance of Context-Specific Development: Efficacy and tolerability in controlled studies with healthy volunteers or in specific patient populations do not always predict performance in the primary target population. The failure of Artefenomel was most pronounced in young African children, where the combined challenges of high disease burden, low immunity, nutritional status, and the practicalities of administering a difficult formulation proved too great. Future development programs must prioritize testing in the most vulnerable and relevant patient populations as early as is ethically and scientifically feasible.

The Legacy of the Endoperoxide Pharmacophore

Despite the failure of Artefenomel as a clinical candidate, the program was not without value. The extensive research conducted has significantly advanced the field of antimalarial science. It has generated a wealth of high-quality PK/PD data that has refined our understanding of endoperoxide pharmacology and helped to validate and improve clinical trial models, such as the induced blood-stage malaria (IBSM) model, which can accelerate early drug development. Furthermore, the specific reasons for Artefenomel's failure have spurred new and innovative chemical approaches, such as the desymmetrization strategy, which offer a clear path forward for designing the next generation of synthetic ozonides.[26] The endoperoxide pharmacophore remains one of the most powerful weapons against the malaria parasite. The quest for a long-acting, single-dose, and easily formulated successor to artemisinin continues, now armed with the hard-won and invaluable lessons from the rise and fall of Artefenomel.

Works cited

1. What is Artefenomel Mesylate used for? - Patsnap Synapse, accessed October 21, 2025, https://synapse.patsnap.com/article/what-is-artefenomel-mesylate-used-for
2. Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers wit - Medicines for Malaria Venture, accessed October 21, 2025, https://www.mmv.org/sites/default/files/content/document/haracterizing%20the%20pharmacological%20interaction%20of%20the%20antimalarial%20combination%20artefenomel-piperaquine.pdf
3. Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood-stage Plasmodium falciparum to predict efficacy in patients with malaria, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11603672/
4. Artemisinin: a game-changer in malaria treatment, accessed October 21, 2025, https://www.mmv.org/malaria/symptoms-and-treatments/treatments-about-ACTs
5. Artemether and Lumefantrine: MedlinePlus Drug Information, accessed October 21, 2025, https://medlineplus.gov/druginfo/meds/a609024.html
6. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated P. falciparum malaria in children under 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial | DNDi, accessed October 21, 2025, https://dndi.org/scientific-articles/2016/am-al-fdc-combos/
7. Artemisinin resistance and artemisinin-based combination therapy efficacy (December 2018) - World Health Organization (WHO), accessed October 21, 2025, https://www.who.int/docs/default-source/documents/publications/gmp/who-cds-gmp-2018-26-eng.pdf
8. Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity - ACS Publications, accessed October 21, 2025, https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00787
9. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers - Oxford Academic, accessed October 21, 2025, https://academic.oup.com/jac/article-pdf/71/9/2620/17430131/dkw174.pdf
10. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers - SciSpace, accessed October 21, 2025, https://scispace.com/pdf/efficacy-of-oz439-artefenomel-against-early-plasmodium-myv0ts99l0.pdf
11. This Chemical Trick Could Turn Losing Malaria Drug Into a Winner ..., accessed October 21, 2025, https://www.ucsf.edu/news/2025/08/430481/chemical-trick-could-turn-losing-malaria-drug-winner
12. Turning the Tide Against Malaria: How a Simple Chemical Shift Could Save Millions, accessed October 21, 2025, https://gmdpacademy.org/news/turning-the-tide-against-malaria-how-a-simple-chemical-shift-could-save-millions/
13. Seeking the Elusive Long-Acting Ozonide: Discovery of Artefenomel ..., accessed October 21, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00299
14. Artefenomel - a novel trioxolane - Medicines for Malaria Venture, accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/artefenomel-novel-trioxolane
15. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria - PubMed, accessed October 21, 2025, https://pubmed.ncbi.nlm.nih.gov/28988541/
16. Artefenomel/ferroquine | Medicines for Malaria Venture, accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/artefenomelferroquine
17. Artefenomel | OZ-439 | CAS#1029939-86-3 | novel trioxolane - MedKoo Biosciences, accessed October 21, 2025, https://www.medkoo.com/products/13212
18. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4700386/
19. artefenomel | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 21, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=refs&ligandId=9971
20. (PDF) Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: An open-label phase 2 trial - ResearchGate, accessed October 21, 2025, https://www.researchgate.net/publication/282765690_Antimalarial_activity_of_artefenomel_OZ439_a_novel_synthetic_antimalarial_endoperoxide_in_patients_with_Plasmodium_falciparum_and_Plasmodium_vivax_malaria_An_open-label_phase_2_trial
21. Artefenomel: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 21, 2025, https://go.drugbank.com/drugs/DB11809
22. OZ-439 | C28H39NO5 | CID 24999143 - PubChem, accessed October 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/oz-439
23. ARTEFENOMEL - precisionFDA, accessed October 21, 2025, https://precision.fda.gov/ginas/app/ui/substances/RIK029813G
24. Artefenomel (OZ439, CAS Number: 1029939-86-3) | Cayman Chemical, accessed October 21, 2025, https://www.caymanchem.com/product/30677/artefenomel
25. Artefenomel Mesylate | DrugBank Online, accessed October 21, 2025, https://go.drugbank.com/salts/DBSALT002081
26. Artefenomel Regioisomer RLA-3107 Is a Promising Lead for the Discovery of Next-Generation Endoperoxide Antimalarials | ACS Medicinal Chemistry Letters, accessed October 21, 2025, https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00039
27. artefenomel | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 21, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9971
28. Interactions of Artefenomel (OZ439) with Milk during Digestion: Insights into Digestion-Driven Solubilization and Polymorphic Transformations | Molecular Pharmaceutics - ACS Publications, accessed October 21, 2025, https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.8b00541
29. NCT03660839 | Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria | ClinicalTrials.gov, accessed October 21, 2025, https://clinicaltrials.gov/study/NCT03660839
30. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection - PMC, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8922009/
31. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection - Oxford Academic, accessed October 21, 2025, https://academic.oup.com/jid/article-pdf/225/6/1062/42897061/jiaa287.pdf
32. Artefenomel (OZ439) | Antimalarial Agent - MedchemExpress.com, accessed October 21, 2025, https://www.medchemexpress.com/artefenomel.html
33. Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity - PubMed, accessed October 21, 2025, https://pubmed.ncbi.nlm.nih.gov/39681556/
34. Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance - MalariaWorld, accessed October 21, 2025, https://media.malariaworld.org/Identifying_a_next_generation_antimalarial_trioxolane_in_a_landscape_of_artemisinin_partial_resistance_3c09c67aa3.pdf
35. Artefenomel | CAS 1029939-86-3 | Cayman Chemical | Biomol.com, accessed October 21, 2025, https://www.biomol.com/products/chemicals/biochemicals/artefenomel-cay30677-1
36. Efficacy of OZ439 (artefenomel) against early Plasmodium ..., accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/efficacy-oz439-artefenomel-against-early-plasmodium-falciparum-blood
37. First-in-man safety and pharmacokinetics of synthetic ozonide ..., accessed October 21, 2025, https://www.researchgate.net/publication/228113791_First-in-man_safety_and_pharmacokinetics_of_synthetic_ozonide_OZ439_demonstrates_an_improved_exposure_profile_relative_to_other_peroxide_antimalarials
38. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers - PMC - PubMed Central, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4992851/
39. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers - Oxford Academic, accessed October 21, 2025, https://academic.oup.com/jac/article/71/9/2620/2238014
40. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed October 21, 2025, https://journals.asm.org/doi/10.1128/aac.01371-19
41. Malaria caused by Plasmodium Falciparum Completed Phase 1 Trials for Artefenomel (DB11809) | DrugBank Online, accessed October 21, 2025, https://go.drugbank.com/indications/DBCOND0021343/clinical_trials/DB11809?phase=1&status=completed
42. Malaria caused by Plasmodium Falciparum Completed Phase 2 Trials for Artefenomel (DB11809) | DrugBank Online, accessed October 21, 2025, https://go.drugbank.com/indications/DBCOND0021343/clinical_trials/DB11809?phase=2&status=completed
43. Plasmodium Infections Completed Phase 2 Trials for Artefenomel (DB11809) - DrugBank, accessed October 21, 2025, https://go.drugbank.com/indications/DBCOND0034555/clinical_trials/DB11809?phase=2&status=completed
44. Artefenomel Completed Phase 2 Trials for Malaria caused by Plasmodium Falciparum ... - DrugBank, accessed October 21, 2025, https://go.drugbank.com/drugs/DB11809/clinical_trials?conditions=DBCOND0021343%2CDBCOND0022743&phase=2&purpose=treatment&status=completed
45. Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria - MESA, accessed October 21, 2025, https://mesamalaria.org/mesa-track/phase-ii-efficacy-study-artefenomel-piperaquine-adults-children-p-falciparum-malaria/
46. Artefenomel Completed Phase 1 / 2 Trials for Malaria Treatment | DrugBank Online, accessed October 21, 2025, https://go.drugbank.com/drugs/DB11809/clinical_trials?conditions=DBCOND0007188&phase=1%2C2&purpose=treatment&status=completed
47. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria - PubMed Central, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5632828/
48. Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood stage Plasmodium falciparum | medRxiv, accessed October 21, 2025, https://www.medrxiv.org/content/10.1101/2024.02.07.24302432v2
49. Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood stage Plasmodium falciparum to predict efficacy in patients with malaria, accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/characterizing-pharmacological-interaction-antimalarial-combination
50. Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria | Medicines for Malaria Venture, accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/randomized-open-label-phase-2a-study-evaluate-contribution
51. CLINICAL TRIAL PROTOCOL NCT03660839, accessed October 21, 2025, https://cdn.clinicaltrials.gov/large-docs/39/NCT03660839/Prot_000.pdf
52. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers | Medicines for Malaria Venture, accessed October 21, 2025, https://www.mmv.org/newsroom/news-resources-search/single-dose-combination-study-experimental-antimalarials-artefenomel
53. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria - PubMed, accessed October 21, 2025, https://pubmed.ncbi.nlm.nih.gov/34011358/
54. Artefenomel Regioisomer RLA-3107 Is a Promising Lead for the Discovery of Next-Generation Endoperoxide Antimalarials, accessed October 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10108391/
55. UC San Francisco Electronic Theses and Dissertations - eScholarship.org, accessed October 21, 2025, https://escholarship.org/content/qt0zn9q0rt/qt0zn9q0rt.pdf